FDA Declines Approval for Breakthrough Hunter Syndrome Gene Therapy, Citing Trial Design Concerns

ROCKVILLE, Md. — The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to REGENXBIO, declining to approve RGX-121, a highly anticipated one-time gene therapy for Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome. The decision, announced by the company on February 9, 2026, marks a significant setback for families and clinicians who have spent decades seeking a treatment capable of halting the neurocognitive decline associated with the ultra-rare genetic disorder.

The FDA’s rejection centered on uncertainties regarding the pivotal trial’s design and the reliability of the biomarkers used to measure success, rather than specific safety concerns. The news sent REGENXBIO shares tumbling 19% in aftermarket trading, reflecting investor anxiety over the regulatory path forward for complex genetic medicines.

The Search for a Neurological Cure

Hunter syndrome is an X-linked recessive disorder that primarily affects males, occurring in approximately 1 in 100,000 to 170,000 births worldwide. It is caused by a deficiency in the iduronate-2-sulfatase (I2S) enzyme. Without this enzyme, complex sugars called glycosaminoglycans (GAGs) build up in cells throughout the body, leading to progressive organ damage, skeletal deformities, and—in its most severe “neuronopathic” form—profound cognitive impairment.

While the FDA approved Elaprase (idursulfase) in 2006 to treat the physical symptoms of the disease, that enzyme replacement therapy (ERT) cannot cross the blood-brain barrier. As a result, while a child’s heart or liver might improve on ERT, their brain continues to suffer irreversible damage.

“Families have waited 20 years for a therapy that addresses the brain,” said Terri Klein, President and CEO of the National MPS Society. “For these boys, time is not just a luxury; it is their cognitive future.”

RGX-121: How the Therapy Works

RGX-121 was designed to solve the blood-brain barrier problem. Using a viral vector (AAV9), the therapy delivers a functional copy of the IDS gene directly into the cerebrospinal fluid. The goal is to turn brain cells into “factories” that produce the missing enzyme, clearing out the toxic GAG buildup.

Data from the CAMPSITE clinical trial appeared promising. REGENXBIO reported that patients treated with RGX-121 showed significant and durable reductions in a specific biomarker, heparan sulfate D2S6, which is closely linked to neurocognitive outcomes. Despite these biological improvements and a generally favorable safety profile, the FDA determined that the evidence was not yet sufficient for accelerated approval.

Regulatory Roadblocks: Three Key Concerns

The FDA’s Complete Response Letter outlined three primary areas of contention:

1. Patient Eligibility: The agency expressed concerns about whether the trial clearly distinguished between “neuronopathic” patients (those with brain involvement) and “attenuated” patients (those with milder forms), potentially muddying the results.

2. Trial Controls: The FDA questioned the “natural history” control arm—a group of untreated patients used for comparison—noting it may not have perfectly matched the characteristics of the boys in the RGX-121 trial.

3. Biomarker Validation: Most critically, the agency questioned whether the reduction of the D2S6 biomarker is a “reasonably likely” predictor of actual clinical benefit, such as improved speech or motor skills.

“The FDA is increasingly scrutinizing surrogate endpoints,” noted one independent analyst. This shift in focus toward long-term clinical outcomes over laboratory markers has become a recurring theme under recent leadership at the FDA’s Center for Biologics Evaluation and Research (CBER).

Safety and the “Clinical Hold” Context

While the FDA did not cite safety as the reason for the rejection, the decision comes on the heels of a recent clinical hold on the RGX-121 program. That hold was triggered by a brain tumor observed in a separate trial for a related therapy, RGX-111 (for MPS I).

However, medical experts point out that AAV integration events—where the gene therapy virus accidentally triggers a mutation—are exceptionally rare. Of the 32 patients treated with RGX-121, none have shown signs of such complications.

“We must balance the theoretical risks of gene integration against the certain fatality of untreated Hunter syndrome,” said Jim Wilson, M.D., Ph.D., a pioneer in the field of gene therapy.

The Path Forward

REGENXBIO plans to request a “Type A” meeting with the FDA to discuss a path toward resubmission. Potential requirements could include a longer follow-up period for existing patients or the enrollment of additional participants to strengthen the data.

“This is devastating for the community, but we remain confident in the science,” said Curran Simpson, President and CEO of REGENXBIO. “We believe RGX-121 has the potential to fundamentally alter the disease trajectory for these children.”

For now, the rejection serves as a reminder of the immense hurdles facing “ultra-rare” disease research. When a disease affects fewer than 1,000 people in the United States, traditional large-scale clinical trials are nearly impossible to conduct.

What This Means for Patients

For parents of children with Hunter syndrome, the news is a heavy blow but not necessarily the end of the road.

• Continued Care: Patients currently on Elaprase (ERT) should continue their treatment as directed, as it remains the standard of care for non-neurological symptoms.

• Clinical Trials: Ongoing trials for RGX-121 may continue to collect data, which could eventually lead to approval.

• Advocacy: Patient groups are expected to increase pressure on regulators to accept “flexible” pathways for ultra-rare conditions where traditional evidence is hard to gather.

“Every day we wait is a day of lost function,” said Dr. Joseph Muenzer, Director of the Muenzer MPS Research and Treatment Center at UNC Chapel Hill. “We need a streamlined process that recognizes the urgency of these fatal neurodegenerative diseases.”

References

• https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-regenxbios-rare-disease-drug-2026-02-09/

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.